Clinical Trials Logo
  1. Home
  2. Pharmacological Action
  3. NCT05453045
  4. Details
NCT05453045 Clinical Trial

Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva

Pharmacological Action Clinical Trial

Official title:
Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva in Healthy Volunteers

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05453045
Other study ID # ABZ0301
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 18, 2022
Est. completion date December 16, 2022

Study information
Verified date July 2022
Source Universidad Nacional de Salta
Contact Alejandro J Krolewiecki, MD
Phone +5491131838673
Email alekrol@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project will develop and assess the feasibility and acceptability of a salive-based assay to monitor adherence to Mass Drug Administration (MDA) campaigns within Soil-transmitted helminthiasis (STH) control programs, evaluating the salive and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites.The final goal is to obtain a field ready tool for the measurement of adherence to anthelmintic treatment at a community level that serves as a coverage/adherence indicator and a reference standard for other monitoring tools.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 12
Est. completion date December 16, 2022
Est. primary completion date August 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: Body Mass Index: 18 to 25. Physical exam without significant abnormal findings. Exclusion Criteria: Pregnancy Lactation Use of ABZ or other benzimidazole drugs in the previous 30 days History of intolerance to ABZ Malabsorption and/or other gastrointestinal conditions that might compromise ABZ absorption.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Albendazole
tablet administration after a meal contaning approximate 15 g of fat

Locations
Country Name City State
n/a

Sponsors (2)
Lead Sponsor Collaborator
Universidad Nacional de Salta Fundacion Mundo Sano

Outcome
Type Measure Description Time frame Safety issue
Primary Salive albendazole levels Albendazole and its metabolites will be measured in salive samples through high performance liquid chromatography (HPLC). 72 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06040853 - Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia? Phase 4
Not yet recruiting NCT05553496 - Assessment of Rituximab Therapeutic Response Versus Conventional Treatment Phase 2/Phase 3
Recruiting NCT05534802 - Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass N/A
Recruiting NCT04190537 - PARADOX - the Incidence of Paradoxical Reactions in Pediatric Patients Premedicated With Midazolam
Completed NCT03119454 - "Corticoid-16" in Long Term When Administered Systemically in Patients in Routine Medical Practice N/A
Completed NCT03522532 - Dental Restorations Effect on Oxidative Status of the Gingival Crevicular Fluid N/A
Unknown status NCT01614353 - Medication-taking Preferences & Practices of Patients With Chronic Conditions N/A
Completed NCT03714360 - The Effect of Tranexamic Acid. A Randomised Study of Patients Undergoing Elective Lumbar Spine Surgery. Phase 4
Recruiting NCT03352622 - Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis N/A
Recruiting NCT06288841 - Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in Gynecologic Laparoscopic Patients: A Randomized, Single-blind, Active-Controlled Clinical Study N/A
Not yet recruiting NCT04320277 - Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. Phase 2/Phase 3
Completed NCT03359590 - Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients Phase 2
Not yet recruiting NCT03904303 - Test of a New Gel-based Colon Cleansing Agent Compared to Moviprep Phase 1
Completed NCT05591105 - Morphine Consumption in the Obese Patients
Completed NCT05428683 - Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery N/A
Enrolling by invitation NCT02985281 - Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients Phase 2/Phase 3
Recruiting NCT06222710 - Ultrasound Guiding Pharmacopuncture Therapy for Supraspinatus Tendinopathy N/A
Not yet recruiting NCT03953287 - Pharmacokinetic Study of Paracetamol. Phase 1
Recruiting NCT03622047 - Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil N/A
Active, not recruiting NCT06324370 - Exploratory Pharmacokinetic Study of Virgin Coconut Oil (VCO) N/A